SCHEMBL22198249

SCHEMBL22198249

Cc1ccc(/C=N/N=C/c2ccc(N(C)C)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.71
▸ NPC1 O15118 4/20 0.71
▸ RAB9A P51151 3/20 0.71
▸ ALDH1A1 P00352 9/20 0.70
▸ TSHR P16473 1/20 0.62
▸ POLB P06746 1/20 0.60
▸ GRIN2D O15399 4/20 0.59
▸ GRIN3B O60391 4/20 0.59
▸ GRIN1 Q05586 4/20 0.59
▸ GRIN2A Q12879 4/20 0.59
▸ GRIN2B Q13224 4/20 0.59
▸ GRIN2C Q14957 4/20 0.59
▸ GRIN3A Q8TCU5 4/20 0.59
▸ KMT2A Q03164 5/20 0.57
▸ MAPT P10636 5/20 0.57
▸ MEN1 O00255 4/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ MAPK1 P28482 2/20 0.57
▸ TP53 P04637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10909091 0.91 GRIN2D (0.68) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL22198126 0.91 GRIN2D (0.68) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL10942218 0.85 NPC1 (0.74) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL11743247 0.84 NPC1 (1.00) SMN1; SMN2NPC1RAB9AALDH1A1GRIN2D
SCHEMBL2608307 0.84 NPC1 (1.00) SMN1; SMN2NPC1RAB9AALDH1A1GRIN2D
SCHEMBL11123647 0.83 ALDH1A1 (0.67) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL22198159 0.83 ALDH1A1 (0.67) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL13315382 0.82 ALDH1A1 (1.00) SMN1; SMN2NPC1ALDH1A1TSHRPOLB
SCHEMBL15255720 0.82 ALDH1A1 (1.00) SMN1; SMN2NPC1ALDH1A1TSHRPOLB
SCHEMBL22198277 0.82 APP (0.68) SMN1; SMN2NPC1RAB9AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF HTA Co., Ltd. (CN) 2021-12-23 — — US disclosed
WO-2020140924-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO AΒ PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF 原子高科股份有限公司 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF MAPT, APP, PSEN1 SMN1; SMN2 2538/4885NPC1 2250/4885RAB9A 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback